154 related articles for article (PubMed ID: 8973608)
1. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans.
Isaacs JD; Wing MG; Greenwood JD; Hazleman BL; Hale G; Waldmann H
Clin Exp Immunol; 1996 Dec; 106(3):427-33. PubMed ID: 8973608
[TBL] [Abstract][Full Text] [Related]
2. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
Brett SJ; Baxter G; Cooper H; Rowan W; Regan T; Tite J; Rapson N
Int Immunol; 1996 Mar; 8(3):325-34. PubMed ID: 8671618
[TBL] [Abstract][Full Text] [Related]
3. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype.
Wing MG; Waldmann H; Isaacs J; Compston DA; Hale G
Ther Immunol; 1995 Aug; 2(4):183-90. PubMed ID: 9358610
[TBL] [Abstract][Full Text] [Related]
4. CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.
Isaacs JD; Manna VK; Rapson N; Bulpitt KJ; Hazleman BL; Matteson EL; St Clair EW; Schnitzer TJ; Johnston JM
Br J Rheumatol; 1996 Mar; 35(3):231-40. PubMed ID: 8620297
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
Walsh M; Chaudhry A; Jayne D
Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469
[TBL] [Abstract][Full Text] [Related]
6. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study.
Weinblatt ME; Maddison PJ; Bulpitt KJ; Hazleman BL; Urowitz MB; Sturrock RD; Coblyn JS; Maier AL; Spreen WR; Manna VK
Arthritis Rheum; 1995 Nov; 38(11):1589-94. PubMed ID: 7488279
[TBL] [Abstract][Full Text] [Related]
7. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.
Lockwood CM; Hale G; Waldman H; Jayne DR
Rheumatology (Oxford); 2003 Dec; 42(12):1539-44. PubMed ID: 12949252
[TBL] [Abstract][Full Text] [Related]
8. Humanized IgG1 and IgG4 anti-CD4 monoclonal antibodies: effects on lymphocytes in the blood, lymph nodes, and renal allografts in cynomolgus monkeys.
Mourad GJ; Preffer FI; Wee SL; Powelson JA; Kawai T; Delmonico FL; Knowles RW; Cosimi AB; Colvin RB
Transplantation; 1998 Mar; 65(5):632-41. PubMed ID: 9521196
[TBL] [Abstract][Full Text] [Related]
9. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.
Dalakas MC; Rakocevic G; Schmidt J; Salajegheh M; McElroy B; Harris-Love MO; Shrader JA; Levy EW; Dambrosia J; Kampen RL; Bruno DA; Kirk AD
Brain; 2009 Jun; 132(Pt 6):1536-44. PubMed ID: 19454532
[TBL] [Abstract][Full Text] [Related]
10. Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Vis M; van der Horst AR; Wolbink GJ; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Lems WF; Nurmohamed MT; Aarden L; Hamann D
Ann Rheum Dis; 2009 Apr; 68(4):558-63. PubMed ID: 18445623
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of CAMPATH-1H in BMT patients.
Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
[TBL] [Abstract][Full Text] [Related]
12. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H.
Brett S; Baxter G; Cooper H; Johnston JM; Tite J; Rapson N
Immunology; 1996 May; 88(1):13-9. PubMed ID: 8707338
[TBL] [Abstract][Full Text] [Related]
13. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.
Gong Q; Hazen M; Marshall B; Crowell SR; Ou Q; Wong AW; Phung W; Vernes JM; Meng YG; Tejada M; Andersen D; Kelley RF
MAbs; 2016; 8(6):1098-106. PubMed ID: 27216702
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis.
Jung SM; Kim HS; Kim HR; Kim NY; Lee JH; Kim J; Kwok SK; Park KS; Park SH; Kim HY; Ju JH
Int Immunopharmacol; 2014 Jul; 21(1):20-5. PubMed ID: 24752013
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials with CAMPATH-I and other monoclonal antibodies.
Hale G; Phillips JM
Biochem Soc Trans; 1995 Nov; 23(4):1057-63. PubMed ID: 8654681
[No Abstract] [Full Text] [Related]
16. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
Simpson D
BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Chakrabarti S; Hale G; Waldmann H
Transplant Proc; 2004 Jun; 36(5):1225-7. PubMed ID: 15251298
[TBL] [Abstract][Full Text] [Related]
18. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
[TBL] [Abstract][Full Text] [Related]
20. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
Siders WM; Shields J; Garron C; Hu Y; Boutin P; Shankara S; Weber W; Roberts B; Kaplan JM
Leuk Lymphoma; 2010 Jul; 51(7):1293-304. PubMed ID: 20377308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
